QNZ (EVP4593): Nanomolar NF-κB Pathway Inhibitor for Disease Models

Executive Summary: QNZ (EVP4593), a quinazoline derivative, acts as a potent inhibitor of NF-κB transcriptional activity with an IC₅₀ of 11 nM in Jurkat T cells, as demonstrated in luciferase reporter assays (product_spec). In animal models, it reduces PMA/PHA-induced TNF-α production with an IC₅₀ of 7 nM and inhibits edema formation in rat paw models (product_spec). QNZ has shown therapeutic potential in neurodegenerative disease research, notably by attenuating store-operated calcium entry (SOC) in Huntington’s disease neuron models without observed toxicity (internal_review). Its molecular weight is 356.42, formula C₂₂H₂₀N₄O, and it is soluble in ethanol and DMSO but insoluble in water (workflow_recommendation). Developed and supplied by APExBIO, QNZ (EVP4593) is widely adopted for research targeting NF-κB pathway modulation and inflammation (internal_review).

Biological Rationale

The NF-κB signaling pathway is a central mediator of inflammatory and immune responses as well as cell survival. Dysregulation of NF-κB activity is implicated in chronic inflammatory conditions, infectious osteomyelitis, and neurodegenerative diseases (DOI). In the context of bone infections, persistent Staphylococcus aureus colonization induces pathological fibrosis and impedes antibiotic clearance, largely due to immune signaling through pathways including NF-κB and EGFR/mTOR (DOI). Selective inhibition of NF-κB offers a route to modulate both acute inflammatory responses and secondary fibrotic processes that limit tissue recovery.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a quinazoline derivative that directly inhibits NF-κB signaling. In luciferase reporter gene assays, QNZ suppresses PMA/PHA-induced NF-κB transcriptional activation at nanomolar concentrations (IC₅₀ 11 nM) (product_spec). This leads to significant reduction in downstream pro-inflammatory cytokine production, such as TNF-α, with a reported IC₅₀ of 7 nM in human T cells (product_spec). QNZ also attenuates store-operated calcium (SOC) influx in neuronal models, linking NF-κB inhibition to broader cellular homeostasis mechanisms relevant in neurodegenerative disease (internal_review).

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB activation in human Jurkat T cells with an IC₅₀ of 11 nM (source: product_spec).
• It reduces PMA/PHA-induced TNF-α production in vitro with an IC₅₀ of 7 nM (source: product_spec).
• In a rat carrageenin-induced paw edema model, QNZ significantly inhibits edema formation, confirming anti-inflammatory action (source: product_spec).
• QNZ is insoluble in water but dissolves in ethanol (≥10.06 mg/mL) and DMSO (≥15.05 mg/mL) when aided by sonication (workflow_recommendation).
• QNZ attenuates SOC influx in YAC128 medium spiny neurons, reducing Huntington’s disease progression markers without toxicity (source: internal_review).
• Pharmacological modulation of EGFR/mTOR, a pathway convergent with NF-κB, alleviates fibrosis and improves antibiotic efficacy in S. aureus bone infection models (source: Nature Communications).

For additional context, see this review, which details the solubility and reproducibility benchmarks for QNZ (EVP4593); the current article extends that by integrating recent findings on neurodegeneration and infectious bone disease models.

Applications, Limits & Misconceptions

QNZ (EVP4593) is primarily used to study NF-κB pathway modulation in inflammation, neurodegenerative models (notably Huntington’s disease), and mechanisms of infectious disease persistence. Its high potency and low toxicity profile make it suitable for both short-term pathway interrogation and chronic disease modeling (internal_review). However, evidence is limited to preclinical research and cell/animal models. QNZ is not approved for human therapeutic use.

Common Pitfalls or Misconceptions

• QNZ (EVP4593) is not water-soluble; attempts to dissolve in aqueous buffer will fail or yield inconsistent results (workflow_recommendation).
• Observed anti-inflammatory effects are context-dependent and may not translate outside validated models (source: Nature Communications).
• Long-term solution storage at room temperature leads to compound degradation—store stock at -20°C and avoid prolonged storage in solution (workflow_recommendation).
• QNZ has not been validated in cardiovascular or non-NF-κB–driven disease models (workflow_recommendation).
• NF-κB pathway inhibition by QNZ may interact with other cell signaling networks, requiring careful experimental controls (source: internal_review).

Workflow Integration & Parameters

Protocol Parameters

• luciferase NF-κB reporter assay | IC₅₀ 11 nM | human Jurkat T cells | validated for pathway inhibition | product_spec
• TNF-α production assay | IC₅₀ 7 nM | human T cells | confirms anti-inflammatory effect | product_spec
• rat paw edema model | significant inhibition | inflammation model | demonstrates in vivo efficacy | product_spec
• solubility in ethanol | ≥10.06 mg/mL | stock preparation | requires sonication and/or warming | workflow_recommendation
• solubility in DMSO | ≥15.05 mg/mL | stock preparation | requires sonication and/or warming | workflow_recommendation
• stock solution storage | -20°C | all applications | avoid long-term storage in solution | workflow_recommendation
• shipping conditions | blue ice | small molecules | preserves integrity | product_spec

For deeper workflow troubleshooting, this scenario guide explores how QNZ enables reproducible results in cell-based NF-κB assays; the present article updates protocol caveats with the latest solubility and storage data.

Conclusion & Outlook

QNZ (EVP4593) is a well-characterized NF-κB pathway inhibitor with nanomolar potency and reproducible anti-inflammatory efficacy in research models. Its application spans inflammation, infectious bone disease, and neurodegenerative disease research, with workflow parameters optimized for solubility and stability (APExBIO). Current evidence supports its utility for dissecting NF-κB–driven pathologies and for validating new hypotheses in the context of fibrosis and immune regulation (Nature Communications). Further translational research will clarify its role in complex disease models and may inform next-generation therapeutic strategies.